Cambridge Healthtech Institute’s 3rd Annual

Bispecific Antibodies for Cancer Immunotherapy

Engineering Next-Generation Biotherapeutics in Immuno-Oncology

August 10-11, 2020



Engaging multiple receptors with bispecific biologics offers the potential to improve upon single-agent checkpoint blockade and promises to be the next generation of immunotherapy. Cambridge Healthtech Institute’s Third Annual Bispecific Antibodies for Cancer Immunotherapy meeting will showcase preclinical, translational, and clinical studies on using bispecific antibodies for dual blockade of checkpoint targets, T cell-redirecting bispecific biologics, and overcoming T cell exhaustion, as well as strategies to improve efficacy and reduce toxicity, and to engineer the next generation of bi- and multi-specific biologics.

Preliminary Agenda

T CELL ENGAGING BISPECIFIC ANTIBODIES

Talk Title to be Announced

Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor

PD1-GITRL Bispecific for Immuno-Oncology

Hamsell M. Alvarez, PhD, Principal Research Scientist II, Oncology Discovery, AbbVie Biotherapeutics

COBRA – A Novel Class of Conditionally Active, T Cell Engaging Bispecifics for the Treatment of Solid Tumors

Bob DuBridge, PhD, Executive Vice President, Research & CTO, Maverick Therapeutics

A Bispecific SNIPER Antibody Demonstrating Preclinical Efficacy through the Selective Elimination of Tumor Tregs

Bonnie J. Hammer, PhD, Vice President, Research & Development, Invenra

XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-Target, Off-Tumor Problem

Volker Schellenberger, PhD, President & CTO, Amunix

BISPECIFIC ANTIBODIES FOR COMBINATION IMMUNOTHERAPY

Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific

Shane Olwill, PhD, Senior Vice President, Head of Translational Science, Pieris Pharmaceuticals GmbH

PD1/OX40 Bispecifics

Fiona Harding, PhD, Senior Research Fellow, Immuno-Oncology Discovery, Abbvie

ENGINEERING BISPECIFIC AND MULTI-SPECIFIC ANTIBODIES

Multispecific MATCH Antibodies Enable Novel Therapeutic Strategies by Targeting Synergistic Immunomodulatory Functions to the Tumor Microenvironment

Alexandre Simonin, PhD, Director, mAb Discovery, Numab Therapeutics AG

Talk Title to be Announced

Mark Throsby, PhD, Executive Vice President & CSO, Merus NV

Modulating the Immune System with Multi-Specific Antibodies

Suhasini Iyer, PhD, CDO, TeneoBio



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Korean